Catalio Capital Management is a New York-based investment firm founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein (son of famed geneticist Bert Vogelstein). The firm manages $2 billion in assets across private equity, private credit, and public equities strategies. It focuses on breakthrough biomedical technology companies founded or backed by serial scientist-entrepreneurs.

Catalio participated in Beacon Biosignals' $86M Series B in November 2025 and has previously invested in Blackrock Neurotech (formerly Blackrock Microsystems) and co-founded MindX (acquired by Blackrock Neurotech). Its broader portfolio spans 80+ companies across drugs, devices, and diagnostics. Catalio raised over $400M for its fourth fund in 2025.

Catalio invests globally with a US-primary focus. For neurotech, it is most relevant to clinically serious companies in BCI, neurodiagnostics, and brain health platforms. Its scientist-entrepreneur sourcing model and Johns Hopkins network give it differentiated access to translational neuroscience companies.